title: Oral/infusion cancer drug parity begins to raise health plan costs.
authors.forename: John
authors.initials: J
authors.lastname: Carroll
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics*; D003669:Deductibles and Coinsurance / Q000191:economics / Q000592:standards; D004333:Drug Administration Routes; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D005252:Fees, Pharmaceutical / Q000331:legislation & jurisprudence*; D006801:Humans; D007262:Infusions, Intravenous / Q000191:economics; D007342:Insurance Benefits / Q000191:economics / Q000592:standards; D007348:Insurance, Health / Q000191:economics* / Q000592:standards; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D014481:United States
chemical_list: D000970:Antineoplastic Agents